// STATE LEGISLATION TRACKER

Pennsylvania SB 507: An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, in public safety, providing for

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Pennsylvania
Bill: SB 507
Filed: 2019-04-03
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Pennsylvania SB507 was an opioid-prescribing bill, not a peptide, compounding, telehealth, or scope-of-practice bill. Based on the title and available status information, it does not appear to affect compounded peptides, off-label peptide prescribing, 503A/503B pharmacies, NPs, naturopaths, or telehealth peptide care.

Key Points

No direct peptide access impact is apparent
Targets opioid prescription limits, not compounded drugs generally
No clear change to 503A or 503B compounding rules
No clear change to NP, naturopathic, or telehealth peptide practice

What to Watch For

Note The available record shows referral to committee on April 3, 2019, with no votes listed.

Note Any impact would be limited to opioid or controlled-substance prescribing, not ordinary peptide prescribing.

Note No available title/status signal points to FDA compounding, off-label use, or peptide-specific restrictions.

Where the Bill Stands

The bill was introduced and referred to committee on April 3, 2019, and the 2019-2020 session ended without passage.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws